EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and NOCIMED, LLC for SYSTEMS, MATERIALS, AND METHODS TO LOCALIZE AND EVALUATE PAIN AND DEGENERATIVE PROPERTIES OF TISSUE UC Case Nos. SF2005-063, SF2005-064, SF2006-113...Exclusive License Agreement • January 6th, 2022 • Aclarion, Inc. • Services-medical laboratories • California
This license agreement ("Agreement") is made effective this 18th day of January, 2008 ("Effective Date"), by and between The Regents of the University of California ("The Regents"), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 and acting through its Office of Technology Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, California 94107, and Nocimed, LLC ("Licensee"), a Delaware limited liability corporation, having a principal place of business at 713 Sandoval Way, Hayward, California 94544.
FIRST AMENDMENT TO MARKETING AGREEMENTMarketing Agreement • January 6th, 2022 • Aclarion, Inc. • Services-medical laboratories
This FIRST AMENDMENT TO MARKETING AGREEMENT (the “Amendment”) is dated and effective as of July 27, 2017 (the “Amendment Date”), by and between NOCIMED, INC. a Delaware corporation with its principal place of business at 370 Convention Way, Redwood City, CA 94063 (“Nocimed”), and NUVASIVE, INC., a Delaware corporation with its principal place of business at 7475 Lusk Boulevard, San Diego, CA 92121 (“NuVasive”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Marketing Agreement (as defined below).
NOCIMED, INC. AMENDMENT NO. 1 TO SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • January 6th, 2022 • Aclarion, Inc. • Services-medical laboratories • Delaware
This Amendment No. 1 to Series B-1 Preferred Stock Purchase Agreement (the “Amendment”) is made as of February 1, 2018 (the “Amendment Effective Date”) by and between Nocimed, Inc., a Delaware corporation (the “Company”), and the purchaser set forth on the signature page hereto (the “Purchaser”).
FIRST AMENDMENT TO RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTSale Agreement • January 6th, 2022 • Aclarion, Inc. • Services-medical laboratories
This FIRST AMENDMENT TO AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “Amendment”) is dated and effective as of February 28, 2020 (the “Amendment Date”), by and among NOCIMED, INC., a Delaware corporation (the “Company”), and the parties set forth on the signature pages hereto. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Co-Sale Agreement (as defined below).
Strategic Collaboration Agreement for Phased Commercialization of the Siemens- compatible NOCISCAN-LS Product of Nocimed, Inc.Strategic Collaboration Agreement • January 6th, 2022 • Aclarion, Inc. • Services-medical laboratories
WHEREAS, Nocimed has CE Marked its NOCISCAN-LS product that is supported by a Clinical Evaluation Report (CER) from a prior clinical study conducted by Nocimed for identifying painful lumbar spinal discs, and for predicting successful discogenic low back pain surgery outcomes.
